Cargando…

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report

The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Tony Zibo, Harik, Lara, Force, Seth, Hadadi, Agreen, Bilen, Mehmet Asim, Brown, Jacqueline T., Carthon, Bradley C., Goldman, Jamie, Kucuk, Omer, Master, Viraj A., Nazha, Bassel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755666/
https://www.ncbi.nlm.nih.gov/pubmed/36530969
http://dx.doi.org/10.3389/fonc.2022.949400
Descripción
Sumario:The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors.